467 related articles for article (PubMed ID: 25858975)
1. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
[TBL] [Abstract][Full Text] [Related]
2. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
[TBL] [Abstract][Full Text] [Related]
3. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
4. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
[TBL] [Abstract][Full Text] [Related]
5. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
[TBL] [Abstract][Full Text] [Related]
6. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
8. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial.
Iqbal J; Serruys PW; Silber S; Kelbaek H; Richardt G; Morel MA; Negoita M; Buszman PE; Windecker S
Circ Cardiovasc Interv; 2015 Jun; 8(6):e002230. PubMed ID: 26047993
[TBL] [Abstract][Full Text] [Related]
9. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
Bundhun PK; Yanamala CM; Huang WQ
BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies.
Gu H; Hua K; Li W; Wang Y; Yang J
Int J Cardiol; 2015 Dec; 201():552-60. PubMed ID: 26334379
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents: a meta-analysis.
Qi-Hua L; Qi Z; Yu Z; Xiao-Long L; Hai-Gang J; Jian-Feng Y; Yi S
Coron Artery Dis; 2015 May; 26(3):259-65. PubMed ID: 25715339
[TBL] [Abstract][Full Text] [Related]
12. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
13. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.
Mehilli J; Richardt G; Valgimigli M; Schulz S; Singh A; Abdel-Wahab M; Tiroch K; Pache J; Hausleiter J; Byrne RA; Ott I; Ibrahim T; Fusaro M; Seyfarth M; Laugwitz KL; Massberg S; Kastrati A;
J Am Coll Cardiol; 2013 Dec; 62(22):2075-82. PubMed ID: 23973699
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials.
Bavishi C; Baber U; Panwar S; Pirrotta S; Dangas GD; Moreno P; Tamis-Holland J; Kini AS; Sharma SK
Int J Cardiol; 2017 Mar; 230():310-318. PubMed ID: 28062139
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials.
Fan J; Du H; Yin Y; Ling Z; Wu J; Xiao P; Zrenner B
Int J Cardiol; 2013 Sep; 167(5):2126-33. PubMed ID: 22703941
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
17. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
Patra S; Chakraborty RN; Pande A; Banerjee S; Jena M; Mandal PC; De SK; Khan A; Das SS; Ghosh D; Nag R
Cardiovasc Revasc Med; 2017; 18(3):160-164. PubMed ID: 28017259
[TBL] [Abstract][Full Text] [Related]
18. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
Park KW; Lee JM; Kang SH; Ahn HS; Yang HM; Lee HY; Kang HJ; Koo BK; Cho J; Gwon HC; Lee SY; Chae IH; Youn TJ; Chae JK; Han KR; Yu CW; Kim HS
J Am Coll Cardiol; 2013 Feb; 61(5):536-44. PubMed ID: 23273394
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
